换一批A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
第一作者：
Peter M,Voorhees
第一单位：
Division of Hematology-Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599-7305, USA. peter_voorhees@med.unc.edu
作者：
医学主题词
肾上腺皮质激素类(Adrenal Cortex Hormones);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 抗独特型(Antibodies, Anti-Idiotypic);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);硼酸化物(Boronic Acids);C反应蛋白质(C-Reactive Protein);地塞米松(Dexamethasone);疾病恶化(Disease Progression);用药计划表(Drug Administration Schedule);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);血液病(Hematologic Diseases);人类(Humans);感染控制(Infection Control);白细胞介素6(Interleukin-6);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);吡嗪类(Pyrazines);挽救疗法(Salvage Therapy)
DOI
10.1111/bjh.12266
PMID
23432640
发布时间
2024-06-10
- 浏览32
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
